BG100599A - Antiviral form and therapeutical method - Google Patents

Antiviral form and therapeutical method

Info

Publication number
BG100599A
BG100599A BG100599A BG10059996A BG100599A BG 100599 A BG100599 A BG 100599A BG 100599 A BG100599 A BG 100599A BG 10059996 A BG10059996 A BG 10059996A BG 100599 A BG100599 A BG 100599A
Authority
BG
Bulgaria
Prior art keywords
derivatives
antiviral
therapeutical method
antiviral agents
agents
Prior art date
Application number
BG100599A
Other languages
Bulgarian (bg)
English (en)
Inventor
Odur Washington
Original Assignee
Radopath Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radopath Limited filed Critical Radopath Limited
Publication of BG100599A publication Critical patent/BG100599A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG100599A 1993-10-19 1996-05-17 Antiviral form and therapeutical method BG100599A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939321558A GB9321558D0 (en) 1993-10-19 1993-10-19 Anti-viral agents
PCT/GB1994/002292 WO1995011028A1 (en) 1993-10-19 1994-10-19 Flavin derivatives as anti-viral agents

Publications (1)

Publication Number Publication Date
BG100599A true BG100599A (en) 1997-02-28

Family

ID=10743784

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100599A BG100599A (en) 1993-10-19 1996-05-17 Antiviral form and therapeutical method

Country Status (26)

Country Link
EP (1) EP0739208A1 (es)
JP (1) JPH09505804A (es)
CN (1) CN1140992A (es)
AP (1) AP620A (es)
AU (1) AU7943794A (es)
BG (1) BG100599A (es)
BR (1) BR9407862A (es)
CA (2) CA2123825A1 (es)
CO (1) CO4520283A1 (es)
CZ (1) CZ113796A3 (es)
EE (1) EE9600057A (es)
GB (2) GB9321558D0 (es)
HR (1) HRP940688A2 (es)
HU (1) HUT76322A (es)
IL (1) IL111338A0 (es)
JO (1) JO1866B1 (es)
MA (1) MA23356A1 (es)
MD (1) MD960168A (es)
NO (1) NO961547L (es)
OA (1) OA10579A (es)
PE (1) PE5596A1 (es)
PL (1) PL314008A1 (es)
SK (1) SK50696A3 (es)
UY (1) UY23844A1 (es)
WO (1) WO1995011028A1 (es)
ZA (1) ZA948191B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07188052A (ja) * 1993-12-27 1995-07-25 Sanwa Kagaku Kenkyusho Co Ltd インターフェロン用作用効果増強剤及び該増強剤とインターフェロンとを含有する抗ウイルス活性増強組成物
US5756479A (en) * 1994-12-29 1998-05-26 Research Development Foundation Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
AU2003299486A1 (en) * 2002-05-10 2004-06-03 The Ohio State University Flavin n-oxides: new anti-cancer agents and pathogen eradication agents
ITTO20020622A1 (it) 2002-07-16 2004-01-16 Dayco Europe Srl Gruppo integrato puleggia-smorzatore torsionale
CN100413866C (zh) * 2002-08-02 2008-08-27 中国人民解放军军事医学科学院放射医学研究所 核黄素衍生物及其制备方法与应用
EP2545788A1 (de) * 2011-07-13 2013-01-16 Martin Hulliger Diätisches Mehrkomponentensystem
JP2018131410A (ja) * 2017-02-15 2018-08-23 ヒノキ新薬株式会社 カスパーゼ−３阻害剤とその用途
CN111565715A (zh) * 2017-10-24 2020-08-21 卢内拉生物技术有限公司 Mitoflavoscin：含靶向黄素的酶通过抑制线粒体呼吸作用消除癌症干细胞(CSCS)
CN114126603A (zh) * 2019-07-09 2022-03-01 帝斯曼知识产权资产管理有限公司 用核黄素或dha降低艾拉弗德的病毒活性

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219545A (en) * 1979-03-23 1980-08-26 Collins Calvin E Treatment of infectious keratoconjunctivitis in animals
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
US4500524A (en) * 1982-09-15 1985-02-19 Trustees Of Boston University Tranquilizing and reducing or preventing seizures
WO1991002529A2 (en) * 1989-08-14 1991-03-07 John Bennett Kizer Product and method for killing abnormal vertebrate cells
JP2727471B2 (ja) * 1989-09-14 1998-03-11 三井農林株式会社 インフルエンザウィルス感染予防剤
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5217716A (en) * 1990-07-18 1993-06-08 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
FR2674753B1 (fr) * 1991-04-02 1995-03-10 Jean Berque Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
WO1993010784A1 (en) * 1991-11-25 1993-06-10 University Of Michigan Therapeutic composition and method for preventing reperfusion injury
JP3073309B2 (ja) * 1992-03-27 2000-08-07 雪印乳業株式会社 シアル酸結合５−デアザフラビン系化合物

Also Published As

Publication number Publication date
GB9321558D0 (en) 1993-12-08
GB9421099D0 (en) 1994-12-07
CA2174552A1 (en) 1995-04-27
BR9407862A (pt) 1997-05-20
OA10579A (en) 2002-06-19
HUT76322A (en) 1997-08-28
WO1995011028A1 (en) 1995-04-27
CO4520283A1 (es) 1997-10-15
PL314008A1 (en) 1996-08-05
CA2123825A1 (en) 1995-04-20
NO961547D0 (no) 1996-04-18
JO1866B1 (en) 1995-12-27
PE5596A1 (es) 1996-04-18
HRP940688A2 (en) 1997-04-30
AU7943794A (en) 1995-05-08
IL111338A0 (en) 1994-12-29
NO961547L (no) 1996-06-19
SK50696A3 (en) 1997-01-08
CZ113796A3 (en) 1996-11-13
MA23356A1 (fr) 1995-07-01
ZA948191B (en) 1995-06-08
HU9601006D0 (en) 1996-06-28
JPH09505804A (ja) 1997-06-10
EP0739208A1 (en) 1996-10-30
UY23844A1 (es) 1995-03-28
AP620A (en) 1997-10-14
GB2283913A (en) 1995-05-24
CN1140992A (zh) 1997-01-22
EE9600057A (et) 1996-10-15
AP9400695A0 (en) 1995-01-31
MD960168A (ro) 1998-04-30

Similar Documents

Publication Publication Date Title
ES541103A0 (es) Procedimiento de obtencion de una composicion para el trata-miento de infecciones virales
MY117892A (en) Therapeutic compounds
RU94013464A (ru) Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции
GEP19981482B (en) Use of 1,3 - Oxatiolan Nucleozides Analoges for Treatment of Hepatitis B
ATE219366T1 (de) Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
EA199901031A1 (ru) Производные бензимидазола
BR9107124A (pt) Novos derivados de acido hidroxamico e de n-hidroxiureia e seu uso
BR9909474A (pt) Formas ii, cristalina e v de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, solvato de etanol de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, composição, composto, uso de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, e, processos para o tratamento de uma infecção viral em um humano e para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol
BG100599A (en) Antiviral form and therapeutical method
ATE82294T1 (de) Therapeutische nukleoside.
MX9805441A (es) Compuestos terapeuticos.
TR200101841T2 (tr) Enfeksiyonlardan korunmak ve enfeksiyon tedavisi için bifosfonatların kullanılmaları
EP0594795A4 (en) MICHELLAMINES USEFUL AS ANTIVIRAL AGENTS, COMPOSITION AND METHOD OF TREATMENT.
ATE141506T1 (de) Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff
ATE110714T1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
ATE383161T1 (de) Kombination von product r mit einem antiviralen mittel in der behandlung von hiv infektionen
ATE183508T1 (de) Therapeutische nukleoside
MX9303985A (es) Nucleosidos terapeuticos.
YU47096B (sh) Antivirusna jedinjenja i postupak za njihovo dobijanje
ES2169117T3 (es) Uso de derivados de 2-aminopurina en el tratamiento y profilaxis de la infeccion por el virus 7 del herpes humano.
ES2062266T3 (es) Uso de quinolil- e isoquinoliloxazol-2-onas para la obtencion de un medicamento destinado para la prevencion de infecciones por virus envueltos por glicoproteinas.
TH17663B (th) การใช้สารออกฤทธิ์แบร์ดีย์ไคนีนสำหรับเตรียมตัวยาหลักเพื่อรักษาโรคติดเชื้อไวรัส
EA200100768A1 (ru) Применение 3-изоксазолидинонов и гидроксиаминокислот для лечения инфекций
MX9400210A (es) Tratamiento de infecciones virales.